text:
The Hobbit: An Unexpected Journey
The "Lord of the Rings" films, adapted by Peter Jackson from J.R.R. Tolkien's seminal fantasy novels, were more than a triumph. They kick-started an entire era of filmmaking. We're living in it: it's one where trilogies are meticulously planned out before a meter of film is shot, where franchises deliberately stretch shallow narratives into multi-film arcs, and where studios mine all things "geek" in search of 'the next big series.'
"Lord of the Rings" started all that brand-name mongering, and it managed to maintain its prestige at the same time. For better or worse, it laid the groundwork for an entire generation of American cinema. The 'New Hollywood' had "Bonnie and Clyde" and "The Wild Bunch"; millennials have Peter Jackson.
And so it goes that ten years after "The Two Towers", we come full circle back to Middle Earth. The Hobbit: An Unexpected Journey is the first of (yet again) three films set to release over three Christmases. But where "Rings" brought wonder and exhilaration (to most,) this latest "epic" just reminds us of all the terrible lessons those first three movies taught Hollywood about how to craft blockbusters.
Like Jackson's last two pictures ("King Kong" and "The Lovely Bones"), this "Hobbit" is stretched paper-thin in terms of narrative and crafted with a much lesser elegance than the "Ring" pictures. It also, as mentioned, embodies everything terrible about Hollywood's "house-style" franchise filmmaking. Sacrificing pace for exposition and sequel set-ups? Theme-park style aesthetics, complete with "state of the art" technological intrusions? Slavish fidelity to source materials; to the detriment of any narrative propulsion?
Check, check, check. All too familiar, and all too prevalent in here.
Odds are, if you're bothering to read this review, you know the story already: young house-hobbit Bilbo Baggins (British actor Martin Freeman) journeys off "for an adventure" with a group of dwarves to help them reclaim their homeland from the dragon Smaug (unseen for 99% of the film.) He, along the way, comes along the 'One Ring' by way of a game of riddles with the iconic CGI creation Gollum (Andy Serkis), and gets to know series hallmark Gandalf (Ian McKellan), who comes and goes throughout. The less said about all this, the better, because to be frank, not a lot happens in this movie, and I want to make sure you get your $14 (or whatever a 3-D surcharge costs nowadays) worth.
There's some battles with Orcs, including a particularly vengeful one Jackson created from scratch to give Tolkien's light yarn ("Journey" represents a mere 6 chapters of the source novel; a little over 100 pages), a more tangible antagonist. But by the end of the film, the dwarves are barely out the front door; their journey hardly begun. Even "Fellowship of the Ring" felt like an epic in of itself, but this feels like a prologue.
In fact, this feels more like a Tolkien-branded Disneyland ride than an actual film. We must spend a good 30 minutes drifting along Bilbo's home with the dwarves in tow; causing a ruckus, mugging ingratiatingly to the camera's crass close-ups, and eventually even singing. Hell, the films 'finale' (if you can call an anticlimactic battle scene that wraps up nothing a finale) feels like a videogame, scrolling from the side as our characters run up a narrow bridge, stylishly knocking off enemies with their signature weapons as if this were "Super Mario Brothers: Wizard Edition." This is cinema by way of a theme park ride.
Maybe I'm saying that, however, because of Peter Jackson's latest new toy. I saw the film in new-fangled "High Frame Rate", aka 48 frames-per-second. Not all theaters will be playing the film in this format, but by the time this film ends in 2014, odds are they will be. It creates a much 'smoother' sense of motion, not unlike what you might find on pre-calibrated HDTV's (it's often called "TruMotion"). Unfortunately, it also erases any "wiggle room" that the texture that film gave to unconvincing costumes, CGI, and sets. Everything here indeed looks real, and unfortunately, real looks pretty cheap.
I've no doubt there's a future in 48fps - I'm a celluloid purist at heart, but even I shudder to imagine the way men like Fincher, Soderbergh, and Scorsese could exploit such a tool. But all Jackson sees fit to use his innovation for is loving shots of butterflies, waterfalls, and green vistas. Never once is it actually used to enhance the storytelling, to provide insight into the characters, or even as the center of a set piece. It's all very pretty to look at, but it feels less like a cinematic achievement than it does an impressive tech demo running in the electronics section of a Wal-Mart.
It's all spectacle, no heart. And before I forget, those susceptible to nausea are to be warned: everyone at the screening I attended confessed it took at least a few minutes to shake off the headaches. This is a "new look" as striking as the shift from celluloid film to digital cameras, and it definitely takes some getting used to.
Now don't get me wrong: fans who have been waiting with baited breath to return to Middle Earth will find a lot to love in "The Hobbit", and there's nothing wrong with that. Like I said, it devotes a half-hour to dwarves hanging out in the hero's home, laughing and partying, with the focus not even on character so much as on atmosphere. This may be the first 'fantasy hang-out' movie: "Dungeons + Dragons" by way of "Dazed and Confused".
So no doubt, those in love with the source material (that is, those who are familiar with the dwarves' personalities past the nonexistent characterizations Jackson offers), will have no qualms seeing their favorite universe explored for another 9 hours. Still, the first trilogy offered three epic, densely plotted pictures, with individual distinctions. Now we're being offered one-third of a children's story without any concessions made to allow it to work as a self-contained film. Even for super-fans, I imagine a hollow feeling will arise. But who knows. Maybe it's just the motion sickness.
The Hobbit: An Unexpected Journey
Gandalf :: Ian McKellen
Bilbo Baggins :: Martin Freeman
Galadriel :: Cate Blanchett
Old Bilbo :: Ian Holm
Saruman :: Christopher Lee
Elrond :: Hugo Weaving
Frodo :: Elijah Wood
Voice of Gollum :: Andy Serkis
Thorin Oakenshield :: Richard Armitage
Thorin Oakenshield :: Manu Bennett
Nori :: Jed Brophy
Ori :: Adam Brown
Oin :: John Callen
Dori :: Mark Hadlow
Gloin :: Peter Hambleton
Thorin Oakenshield :: Barry Humphries
Bombur :: Stephen Hunter
Bifur :: William Kircher
Radagast :: Sylvester McCoy
Thorin Oakenshield :: Bret McKenzie
Dwalin :: Graham McTavish
Bofur :: James Nesbitt
Fili :: Dean O'Gorman
Thorin Oakenshield :: Conan Stevens
Balin :: Ken Stott
Kili :: Aidan Turner
Producer, Fran Walsh; Screenwriter, Philippa Boyens; Screenwriter, Guillermo del Toro; Producer, Carolynne Cunningham; Producer, Zane Weiner; Executive Producer, Alan Horn; Executive Producer, Toby Emmerich; Executive Producer, Ken Kamins; Executive Producer, Carolyn Blackwood; Producer, Peter Jackson; Cinematographer, Andrew Lesnie; Production Design, Dan Hennah; Film Editor, Jabez Olssen; Casting, Amy Hubbard; Casting, John Hubbard; Casting, Victoria Burrows; Casting, Scot Boland; Casting, Liz Mullane; Casting, Ann Robinson; Costume Designer, Ann Maskrey; Costume Designer, Richard Taylor; Costume Designer, Bob Buck; Original Music, Howard Shore; Set Decoration, Simon Bright; Art Director, Andy McLaren; Art Director, Brad Mill; Art Director, Brian Massey; Set Decoration, Ra Vincent; Costume Designer, Richard Taylor.


text:
The reward has been increased for information that leads to the arrest and conviction of the suspect who assaulted a 92-year-old man for his bible and eyeglasses.
Ricardo Velez, 92, was followed into his apartment building on West 18th Street in Manhattan on Monday night and knocked to the ground, according to the NYPD.
The suspect stole the man's bag which contained the items. The elderly man reportedly suffered a broken hip in the attack.
An initial reward of $12,000 was increased to $22,000 with the additional money coming from the Mayor's Office.
Surveillance video of the attack which was released on Thursday shows the suspect wearing a red cap and black T-shirt and walking with a limp.
He is described by police as a man in his 30s.
Anyone with information is encouraged to contact the NYPD Crime Stoppers at any of the following:
Crime Stoppers at (800) 577-TIPS (8477)
Text your tips to CRIMES (274637), then enter TIP577
Police say that all calls are confidential.
KSAZ-TV & KUTP511 W. Adams St.Phoenix, AZ 85003Phone: (602) 257-1234Fax: (602) 262-0177

subset: commoncrawl


text:
Endoscopic Ultrasonography
- Home
- Health Information
- Endoscopic Ultrasonography
Reasons for Test
- Diagnose or find the cause of a pain or abnormality in the digestive tract
- Locate and view tumors or abnormalities in the pancreas, bile ducts, and chest cavity
- Understand the extent of certain cancers and whether they have spread to lymph glands or other vital organs
- Take tissue samples ( biopsy ) to diagnose a condition
- Provide needle aspiration (to drain a cyst)
Possible Complications
- Infection
- Bleeding
- Mild sore throat for 1-2 days
- Reaction to sedatives
- Regurgitation of stomach contents into the lungs
- Damage to digestive tract
- Advanced age
- Having other medical conditions
What to Expect
Prior to Test
- Avoid eating or drinking (not even water) for at least six hours before the test.
- Take a special cleansing solution, laxative, or enema. This will clean out your intestines. You may also be asked to follow a clear liquid diet.
- Arrange for a ride home after the test if you have to take a sedative.
Description of the Test
|Copyright © Nucleus Medical Media, Inc.
After Test
- Rest when you get home.
- When you feel ready, resume your normal diet.
- Wait until the sedative wears off before you operate machinery, drive, or make any major decisions. You may need to wait 24 hours.
- Take medicine as directed.
How Long Will It Take?
Will It Hurt?
Call Your Doctor
- Pain or discomfort that does not go away or worsens
- Vomiting blood, blood in stool, or dark black stool
- Indigestion
- New or unusual symptoms
American Society for Gastrointestinal Endoscopy http://www.asge.org
National Institute of Diabetes and Digestive and Kidney Diseases http://www.niddk.nih.gov
Canadian Association of Gastroenterology http://www.cag-acg.org
Crohn's and Colitis Foundation of Canada http://www.ccfc.ca
Jacobson B, Chak A, et al. Quality indicators for endoscopic ultrasonography. American Journal of Gastroenterology. 2006;101:898-901.
Quality indicators for endoscopic ultrasonography. AHRQ National Guideline Clearinghouse website. Available at: http://www.guideline.gov/summary/summary.aspx?doc%5Fid=9298&nbr=4968&ss=6&xl=999. Published April 2006. Accessed June 16, 2009.
Understanding EUS (endoscopic ultrasonography). American Society for Gastrointestinal Endoscopy website. Available at: http://www.asge.org/PatientInfoIndex.aspx?id=380. Accessed June 16, 2009.
Revision Information
- Reviewer: Daus Mahnke, MD
- Review Date: 09/2013 -
- Update Date: 09/30/2013 -


text:
I will give you 1,000 acres of land on Planet Orgy for your people if you aid us in this military conflict.
Moderators: Moronstudios, Killer Karetsu
Zupponn wrote:Colette wrote:You're free to make your own map from scratch, however.
All you have to do is flatten his head.
mgb519 wrote:Seriously, you are now the first ever forum superhero.
Colette wrote:I hereby acknowledge Silverdream as the one and only forum troll as agreed in the bet.
Quantumsurfer wrote:No, I have 2 silver.
stubby wrote:omg noob, balrogs are maiars too, don't you know anything
Return to Reports From the Field
Users browsing this forum: No registered users and 3 guests


text:
When it comes to the restaurant equipment you need, KaTom is proud to offer Traulsen products! Traulsen came to be in 1938 and has been producing high quality refrigeration ever since. With a mission to develop only the best, most heavy duty products in the food service industry, Traulsen is a brand name you can trust. And all Traulsen products, with the exception of RAC air curtain refrigerators, come with a standard 3-year parts and labor warranty, plus a five-year warranty on all commercial refrigeration compressors. KaTom Restaurant Supply sells Traulsen products for competitive prices you won't be able to pass up! Find the best blast chiller, refrigerator, or holding cabinet for your needs by shopping KaTom's Traulsen section!
Traulsen Reach In Refrigerators
Traulsen reach in refrigerators are a superior choice for those who desire dependability in their refrigeration. Because Traulsen reach in refrigerators are manufactured with only the most heavy duty materials, like stainless steel, you can bet they will last. KaTom kept your business's budget in mind when pricing Traulsen reach in commercial refrigeration. Why wait? Browse this selection of Traulsen reach in commercial refrigeration today!
Traulsen Display Merchandisers
Increasing the number of impulse purchases your customers make is as easy as using a Traulsen refrigerated display from KaTom! Traulsen refrigerated display units feature glass doors for easy viewing and heavy duty construction that's sure to last. When guests see your products being shown off inside the lighted interior of a Traulsen merchandiser refrigerator, they're sure to buy! Find the best Traulsen merchandiser refrigerator for your needs today!
Traulsen Equipment Accessories
Find everything from extra shelving to casters when you browse KaTom's selection of Traulsen refrigeration parts! Replacing Traulsen refrigeration parts on your unit is both easy and affordable with KaTom's low pricing. KaTom Restaurant Supply even sells Traulsen equipment accessories like equipment bases. Choose the Traulsen equipment accessories you need today with your friends at KaTom Supply!
Traulsen Reach In Freezers
Traulsen commercial reach in freezers are perfect for small and large businesses alike! There are Traulsen reach in restaurant freezers in 1 section models as well as larger 3 section models so finding the right size should be as simple as browsing. Traulsen reach in restaurant freezers feature heavy duty stainless steel and aluminum exteriors for superior durability in the field. Make KaTom your choice for Traulsen reach in restaurant freezers by purchasing today!
Traulsen Miscellaneous Equipment
Efficiently store your seafood or poultry in a Traulsen fish refrigerator from KaTom! Because many Traulsen fish refrigerators feature several drawers, you can rest assure that each type of fish can be stored separately so as not to impart flavors to other types. Other than Traulsen drawer refrigerators, KaTom also sells 2 section models to suit your needs. Order the Traulsen drawer refrigerator you need for a low KaTom price today!
Traulsen Undercounter Refrigeration
When it comes to flexibility, there's nothing like a Traulsen undercounter refrigerator! These Traulsen undercounter refrigerators are made with heavy duty, durable materials and save space by adding extra surface room for your employees to work with. KaTom Restaurant Supply also sells Traulsen undercounter freezers for your colder ingredients. Order the Traulsen undercounter freezer you need today to save with KaTom Supply's low pricing.
Traulsen Heated Cabinets
KaTom Restaurant Supply is bringing the heat with a great selection of Traulsen heated food cabinets! If you're looking to save energy you'll be happy to see that KaTom carries Traulsen heated food cabinets that are Energy Star certified. Whether you're looking for a reach in or pass thru Traulsen heated food cabinet model, KaTom has you covered with competitive pricing. Make your Traulsen heated food cabinet purchase today to save!
Traulsen Dual Temp Refrigeration
Choose the refrigeration you can trust in: Traulsen dual temperature refrigeration! Each Traulsen dual temperature refrigeration piece is made with the most heavy duty, durable materials available to ensure dependability. No matter if you prefer a Traulsen refrigerator freezer with full or half doors, KaTom has you covered. Order a Traulsen refrigerator freezer today from your food service friends at KaTom Restaurant Supply!
Traulsen Roll In Refrigeration
If you own a buffet or catering business, Traulsen roll in refrigeration is the ideal choice for you! Save time and man power by rolling entire racks of pastries or salads into a Traulsen roll in refrigerator. KaTom even carries correctional Traulsen roll in refrigeration for your facilities needs! Experience the quality of fine Traulsen roll in refrigerators by ordering your establishment's model with KaTom!
Traulsen Prep Tables
Save time in your pizza parlor by using a Traulsen pizza prep table! Traulsen pizza prep tables help to keep your ingredients organized and easy to access while maintaining safe temperatures. These units can also be used as Traulsen salad prep tables or even for sandwiches. Choose the best Traulsen salad prep tables for your needs today by shopping with KaTom Restaurant Supply!
Traulsen Refrigerated Equipment Stands
Save space while adding additional refrigerated storage by ordering a Traulsen restaurant equipment stand with KaTom. You'll find that Traulsen restaurant equipment stands are made with heavy duty materials, like stainless steel, so they'll withstand the hustle bustle of the commercial kitchen. KaTom's selection of Traulsen refrigerated equipment stands come in several size options to best meet your needs. Order the Traulsen refrigerated equipment stand you need today with KaTom!


text:
Just hours after confronting one Fox 5 reporter in Manhattan, Alec Baldwin loaded up his car and unloaded on yet another Fox 5 reporter Friday afternoon.
Baldwin told Linda Schmidt to "get the [expletive] out of here" after confronting her and demanding an apology. He falsely accused her of almost hitting his wife with a microphone.
"I asked you a question: You want to apologize to her?" he yelled. He then told a uniformed cop that he wanted to press charges against "that blonde."
Earlier in the day, the actor walked up to Fox 5 reporter Robert Moses and warned him to leave the sidewalk in front of his building (CLICK FOR VIDEO).
Baldwin later issued a statement on the website of MSNBC, the network that carries his weekly talk show, apologizing to his fans and colleagues. MSNBC pulled Baldwin's show, "Up Late," from its schedule for two weeks.
"I did not intend to hurt or offend anyone with my choice of words, but clearly I have -- and for that I am deeply sorry," Baldwin said in the statement. "Words are important. I understand that, and will choose mine with great care going forward. What I said and did this week, as I was trying to protect my family, was offensive and unacceptable. Behavior like this undermines hard-fought rights that I vigorously support."
Baldwin was likely referring to the expletives he yelled at a photographer this week. He did not specifically reference the incidents with Fox 5's Moses and Schmidt.
Moses and Schmidt have been covering the trial of Canadian actress Genevieve Sabourin, who was accused and then convicted this week of stalking Baldwin and his wife. Baldwin and the office of Manhattan District Attorney Cyrus Vance Jr. said it was a case of an acquaintance with a movie star turning into harassment. Sabourin claimed it was a romance that fell apart.
A judge sentenced Sabourin to 195 days in jail for stalking the Baldwins. That sentence came on top a 30-day contempt of court sentence he handed down Wednesday because she kept disrupting the court proceedings with outbursts.
The Associated Press contributed to this report.
Phone: (952) 944-9999
Didn't find what you were looking for?
All content © Copyright 2000 - 2014 Fox Television Stations, Inc. and Worldnow. All Rights Reserved.
Privacy Policy | New Terms of Service What's new | Ad Choices


text:
Evening ReadingBoth the evening and the weekend are upon us again, whether they've been confirmed or not. Not to mention that Apple named Weekend Confirmed one of the best audio podcasts in its Best of 2010 feature on the iTunes Music Store. I think that deserves a round of applause. Horn tooted.
With the holidays and 2011 right around the corner, overeating and overspending become the current priorities, as is avoiding the bony, groping hands of Old Man Winter. (He's one creepy dude.) Pretty much all of the big games for 2010 have already been released as well, meaning that between now and... well, January, it's backlog clobberin' time. Honestly, I'm just glad to be back into the swing of things after a week of vacation-induced sickness.
So, grab a cup of hot chocolate (or an Irish coffee, if that's your thing), curl up by the fire, and wrap yourself in some nice warm chatty.
- News of the Day
- Comprehensive Fallout: New Vegas Patch on the Way
- Weekend Confirmed: Episode 38
- Civilization 5 Thanksgiving-themed DLC Coming Dec 16
- Mass Effect 2 Dated for PS3 in North America and Europe
- Links from Morning Discussion and Around the Web
- 10 Fascinating Last Pictures
- Episode 2: Steph and Lance "Wine Hoes" (Starring DelRio)
- The Micros: Pilot Episode - A Hilarious Must-see for Texas Hold'em Players
You must be logged in to post.


text:
Wrongful Death
Has a loved one died because of another person or company's negligence or deliberate actions? If a family member has died of something other than natural causes, and you believe someone else is to blame, then you may have grounds for a wrongful death lawsuit. A wrongful death attorney or personal injury lawyer can evaluate the specifics of your situation to help determine whether a wrongful death lawsuit would be successful.
In general, you can pursue a wrongful death claim if a family member dies as a result of another person or company's:
- Negligence
- Reckless act
- Intentional act
Examples of negligence would include drunk driving and allowing safety hazards to exist on a piece of real estate. Reckless acts would include drag racing or playing with a loaded handgun, whereas intentional acts include murder.
Types of Wrongful Death Cases
Wrongful death can occur in many ways:
- Accidents
- Murder
- Product failure
- Work accident
- Sports injury
If an action causes the premature loss of life, then you potentially have a reason for a wrongful death lawsuit.
Settlement for Wrongful Death
When a person is killed in an accident, survivors are entitled to fair compensation for their losses. In fact, family members can file a wrongful death lawsuit even if the person or company at fault is facing criminal charges for the death.
While monetary settlements will not bring back your loved one, it can help you continue with your life with fewer disruptions, particularly if the loved one who died was your family breadwinner. A settlement provided guaranteed income to the family.
A wrongful death lawyer or personal injury attorney can help protect your rights and the rights of survivors. In that traumatic time it is still important to look to the protections of the legal system. Your wrongful death attorney will stand by your side and stand up for your rights.
Find a Local Wrongful Death Attorney
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- Types of Spinal Cord Injuries and How They Can Affect Your Settlement
- Personal Injury Case Against Resident of Another State: Must Lawyers File in Federal Court?
- How Do I Open a Personal Injury Claim
- Negotiating a Fair Pain and Suffering Accident Settlement
- Personal Injury Claim After Bike Accident: How Much Can I Expect?
- More Personal Injury Articles


text:
Mealamu set to join '100 club'
All Blacks hooker Keven Mealamu will join an exclusive group when New Zealand face Australia in the third Bledisloe Cup Test in Brisbane on 20 October.
He will become only the third player - after current captain Richie McCaw and former full-back Mils Muliana - who will represent his country in 100 Tests, something which the 33-year-old finds difficult to believe.
"It's a real privilege," Mealamu told Fairfax Media when talking about playing for the All Blacks.
"It's hard to put into words," Mealamu said.
"You never think of playing 100 games for the All Blacks. It's always about trying to be here.
"When I finish my career I'll be able to look back on it.
"It's a very elite group to be apart of. There's not many that have been able to achieve that. I've played with Richie and Mils for a long time; it's very special to join them."
The Blues captain made his debut for New Zealand in 2002 against Wales at the Millennium stadium in Cardiff and said not much has changed since that day.
"I still get those butterflies when I run out onto the field," he revealed.
"The only difference is I know what to expect. When you go into Test rugby you're sort of lost in the hype a little bit.
"Now I know how difficult it's going to be out there. It's good to be able to draw upon those experiences."


text:
42 U.S. Code § 3796c - Administrative provisions
(a) Rules, regulations, and procedures
The Bureau is authorized to establish such rules, regulations, and procedures as may be necessary to carry out the purposes of this subchapter. Such rules, regulations, and procedures will be determinative of conflict of laws issues arising under this subchapter. Rules, regulations, and procedures issued under this subchapter may include regulations governing the recognition of agents or other persons representing claimants under this subchapter before the Bureau. The Bureau may prescribe the maximum fees which may be charged for services performed in connection with any claim under this subchapter before the Bureau, and any agreement in violation of such rules and regulations shall be void.
(b) Use of State and local administrative and investigative assistance
In making determinations under section 3796 of this title, the Bureau may utilize such administrative and investigative assistance as may be available from State and local agencies. Responsibility for making final determinations shall rest with the Bureau.
(c) Use of appropriated funds to conduct appeals
Notwithstanding any other provision of law, the Bureau is authorized to use appropriated funds to conduct appeals of public safety officers' death and disability claims.
(d) References to provisions outside this subchapter
Unless expressly provided otherwise, any reference in this subchapter to any provision of law not in this subchapter shall be understood to constitute a general reference under the doctrine of incorporation by reference, and thus to include any subsequent amendments to the provision.
Source(Pub. L. 90–351, title I, § 1205, formerly § 1204, as added Pub. L. 98–473, title II, § 609F,Oct. 12, 1984, 98 Stat. 2100; renumbered § 1205,Pub. L. 100–690, title VI, § 6106(a)(1),Nov. 18, 1988, 102 Stat. 4341; amended Pub. L. 105–180, § 2(b),June 16, 1998, 112 Stat. 511; Pub. L. 112–239, div. A, title X, § 1086(b)(1)(F),Jan. 2, 2013, 126 Stat. 1967.)
Prior Provisions
A prior section 3796c,Pub. L. 90–351, title I, § 1204, as added Pub. L. 96–157, § 2,Dec. 27, 1979, 93 Stat. 1221, contained provisions similar to this section, prior to the general amendment of this subchapter by section 609F ofPub. L. 98–473.
Another prior section 3796c,Pub. L. 90–351, title I, § 704, as added Pub. L. 94–430, § 2,Sept. 29, 1976, 90 Stat. 1347, contained provisions similar to this section, prior to the general amendment of this chapter by Pub. L. 96–157.
2013—Subsec. (d). Pub. L. 112–239added subsec. (d).
1998—Subsec. (c). Pub. L. 105–180added subsec. (c).
Effective Date of 2013 Amendment
Amendment by Pub. L. 112–239effective Jan. 2, 2013, and applicable to matters pending on Jan. 2, 2013, or filed or accruing after that date, with certain exceptions, see section 1086(d) ofPub. L. 112–239, set out as a note under section 3791 of this title.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.
|Description of Change
|Session Year
|Public Law
|Statutes at Large
|§ 3796c
|112-239 [Sec.] 1086(b)(1)(F)
|126 Stat. 1967
LII has no control over and does not endorse any external Internet site that contains links to or references LII.


text:
Home |
Shoes |
All-White Classics |
Classics |
Size |
8.5 |
- Princess (Wide D)
Free Shipping & Returns*
Rated 4 out of 5Â by 103 reviewers.
Women Casual Shoes
Princess (Wide D)
White (30500)
Size Chart
+ Save To Wishlist
Was this product information helpful?
Thank you for your feedback.
How can we improve this product description?
Your feedback has been submitted. Thank you.
Rated 5 out of 5Â by Pam Most comfortable Shoe Since I had surgery on my foot 2 years ago, this is the only shoe I can wear all day. There are no seams to irritate the incision area, which probably always will be overly sensitive. And with Reesboks excellent construction they wear extremely well, and look good on. 3/23/12
Rated 5 out of 5Â by SHERRY Princess -Wide I have been buying my mother a pair of Princess shoes every year for over 30 years (either for her birthday or for Mother's Day). I have been looking for the wide size now and haven't had any luck either at the stores or online. I was so happy to find your website. I ordered a pair and had them shipped to her. You can't beat your price (and free shiipping)! They arrived a day before she was going out of town with her friends.. She said she wore them straight out of the box with no breaking in. She said she liked the fact that they were already laced. She wore them all weekend without any swelling in her feet. She called me when she got home and said they were the best feeling shoes she has had. This was her first pair in the wide size. Since she liked them so much; I ordered her another white pair, and also a black pair which I am putting back to give her later. Thanks again for making my shopping so fast and easy! Sherry 5/30/12
Rated 5 out of 5Â by monica A Classic for many years The Princess wide shoe has been worn by myself for work and play for many years. They are a quality shoe that fits and wears well. They are very comfortable and long lasting. I recommend this shoe to everyone....and they have it not only in white but black as well. Reebok, thanks for giving us such excellent products. I will always be one of your best customers. 9/21/11
Rated 4 out of 5Â by BeverlyD Been wearing for over30 years I have been wearing these shoes for over 30 years. I buy 6 pair a year. I do the SGK 3 day 60-mile walks every year and always walk to train. Being flat footed, these are the only shoes I can wear. But they have changed, and at times have caused ingrown toenails which require surgery. I wish they would go back to the old version, I would continue to buy them instead of trying to find another shoe. I usually buy 3 pair at a time, so sometimes I don't realize there is a problem right away! 11/11/13
Rated 2 out of 5Â by needwidedeeptoebox Why change a good shoe to crazy? This morning I just received my 8 1/2 Wide Princess. The foot bed is glued in, so no room to insert my orthotics. The toe box is too narrow and squeezing my toes together. There is no arch support in the shoe, it's like walking on a plank of wood. Where the tonge is sewn in, the overlap/excess material is rubbing my foot. Shoes made in indonesia. I've worn Reebok Classic Leather 8 1/2 wide for YEARS, but now they do not make them in wide! So, I had to try these skinny Princess so-called wide. Why doesn't Reebok shoe-makers read what customers are saying, and start making the shoes they've been making for years, and that people wore for years? They are too busy designing shoes for teenagers, in florescent colors! 1/31/13
Rated 3 out of 5Â by Julie25 They were the most comfortable shoes ever But the newer ones made with synthetic upper and non-moulded inner soles are not as nice to wear as the previous leather upper ones. The synthetic leather shoes are very disappointing, not as comfortable to wear, as feet get hot and sticky, unlike the leather ones that allow feet to breath when being worn all day. original shoes from about 10 years ago had a moulded inner to support arch in foot, this is also missing. am now wearing my old tatty ones in preference, as they allow me to stand in them all day without getting sore feet.... please let me know if leather uppers are available again in this style. Many thanks. 3/6/14
Rated 1 out of 5Â by Montana Disappointed! Have worn the Reebok Princess for years...the most comfortable shoe I have. Just ordered another pair, and they are not the same shoe! They seem more snug and tighter, and the upper material does not look or feel like leather! Will return them tomorrow... 5/16/13
Rated 1 out of 5Â by kayeswan This product is now terrible I have purchased the Reebok Princess Aerobic shoe for years in both black and white. Got a new pair about 6 months ago and I can't wear them. I kept waiting for them to break in, but they never did. THEN I discovered why. They went from being leather to this synthetic stuff that will never break in. So $50 down the toilet. Won't be buying Reeboks again. 3/25/14
Rated 4 out of 5Â by Barb34 Love the product, but sizing seems different Have worn for many years, but for past 2 purchases of Princess, even though I buy WIDE, they are too narrow and I haven't been able to wear them. I note that both of these pair were made in Vietnam, and in the past years they were made in Cambodia and/or Pakistan. I'm beginning to think that this might have some bearing on the sizing. My important question is "do Reebok Princess sneakers come in XTRA WIDE? If they do, I will be happy to buy them again. Thanks for letting me explain my concern. 7/22/13
Rated 1 out of 5Â by Sandy disappointed I have bought these shoes for years and am very disappointed that they have taken out the arch support. I would NO longer recommend this shoe. I am very very disappointed because it is hard to find a good shoe anymore. 2/26/12


text:
Workshop Opens Dialogue on Cancer Clinical Trials
Experts on clinical trials met last week to share ideas about how to improve a system that has served the nation well for decades but needs to be modified and updated to meet the needs of patients and its many stakeholders.
A major theme of this workshop was that the reform must be global and include regulatory agencies, third-party payers, and funding entities, such as NCI and pharmaceutical companies, noted NCI Director Dr. John Niederhuber, who delivered opening remarks. Read more
Androgen Deprivation No Better than Conservative Approach in Localized Prostate Cancer
Using androgen deprivation therapy alone in older men with localized prostate cancer does not improve survival outcomes when compared with a conservative management approach, according to a new analysis in the July 8 Journal of the American Medical Association. For localized prostate cancer, androgen deprivation therapy has become a common treatment, despite a lack of definitive evidence that it is more effective than other options, noted the study authors.
To conduct the study, the researchers, from The Cancer Institute of New Jersey, used data from NCI's Surveillance, Epidemiology, and End Results (SEER) program and linked Medicare files to compare the outcomes in men aged 66 and older, who were diagnosed with localized prostate cancer between 1992 and 2002 and had not undergone surgery. Of these men, nearly 8,000 received androgen deprivation therapy and approximately 11,400 were treated with conservative management, often called "watchful waiting." Read more
Workshop Opens Dialogue on Cancer Clinical Trials
Experts on clinical trials met last week to share ideas about how to improve a system that has served the nation well for decades but needs to be modified and updated to meet the needs of patients and its many stakeholders.
A major theme of this workshop was that the reform must be global and include regulatory agencies, third-party payers, and funding entities, such as NCI and pharmaceutical companies, noted NCI Director Dr. John Niederhuber, who delivered opening remarks.
More than 100 individuals representing government, regulatory agencies, academia, industry, and patient groups attended the Institute of Medicine's National Cancer Policy Forum event, held June 1-2 at the Keck Center of the National Academies. The focus was multicenter, final-stage clinical trials and the role of NCI's Clinical Trials Cooperative Group program.
The Cooperative Group program enrolls approximately 22,000 cancer patients each year in clinical studies at academic medical centers, cancer centers, community hospitals, and private research institutions. Congress started the program in 1955, and it has grown to include 1,700 institutions within 10 national groups.
The program has been instrumental in demonstrating the safety and effectiveness of many cancer therapies. But the current clinical trials system has not kept pace with the development of new combinations of therapies that target multiple pathways of cancer.
"The meeting generated a comprehensive and well-informed list of issues and needs that require attention," said Dr. Niederhuber. "It also produced some excellent ideas for positive change. These suggestions will certainly inform NCI's plan of action in the weeks ahead, as we continue our work to enhance this crucial - and rapidly evolving - clinical research enterprise."
Other topics discussed included the recruitment of patients and physicians; costs and payments; and regulatory issues such as data collection standards to establish safety and efficacy.
There seemed to be general agreement on some basic issues, including the need to prioritize the most important trials. Doing fewer trials could allow planners to shift precious resources from poorly accruing trials to other studies.
The annual funding for the Cooperative Groups is approximately $145 million, which is administered by the Cancer Therapy Evaluation Program of NCI's Division of Cancer Treatment and Diagnosis. In 1997, an independent review panel said that the Cooperative Group program needed to be properly funded, and since then the costs of running trials have risen without similar budget increases.
"We must confront not only the crucial scientific questions, but also address funding issues and long-range inefficiencies in the clinical trials system," said Dr. Niederhuber.
Dr. John Mendelsohn, president of the University of Texas M.D. Anderson Cancer Center, chaired the workshop planning committee. He predicted that Cooperative Groups are increasingly going to turn to industry for financial support. These groups are attractive to companies because they offer a greater diversity of patients than many companies can recruit. Another asset is that some groups have tissue banks, and some can look at the expression of genes and molecular targets in real time.
"As we're moving into more personalized medicines, these groups can carry out the kinds of trials we are all interested in," Dr. Mendelsohn said.
During a panel discussion about the collection of data on safety and efficacy, Dr. Richard Pazdur of the Food and Drug Administration (FDA) suggested that the topic could be explored in a future workshop or public forum, as has been done previously with the American Society of Clinical Oncology (ASCO).
The president of ASCO, Dr. Richard Schilsky, responded to the offer immediately by saying his organization would be "delighted" to work with the FDA and other stakeholders to discuss developing data sets required for regulatory approval.
Dr. Harold Moses, director emeritus of the Vanderbilt-Ingram Cancer Center and chair of the National Cancer Policy Forum, noted that previous reviews of NCI Cooperative Groups did not lead to action and said that this time would be different.
A workshop summary will discuss areas of broad agreement, and this could be the basis for an Institute of Medicine study committee. Such a group could form and make recommendations, potentially by next spring.
"Everyone here is interested in action," said Dr. Mendelsohn.
—Edward R. Winstead
Androgen Deprivation No Better than Conservative Approach in Localized Prostate Cancer
Using androgen deprivation therapy alone in older men with localized prostate cancer does not improve survival outcomes when compared with a conservative management approach, according to a new analysis in the July 8 Journal of the American Medical Association. For localized prostate cancer, androgen deprivation therapy has become a common treatment, despite a lack of definitive evidence that it is more effective than other options, noted the study authors.
To conduct the study, the researchers, from The Cancer Institute of New Jersey, used data from NCI's Surveillance, Epidemiology, and End Results (SEER) program and linked Medicare files to compare the outcomes in men aged 66 and older, who were diagnosed with localized prostate cancer between 1992 and 2002 and had not undergone surgery. Of these men, nearly 8,000 received androgen deprivation therapy and approximately 11,400 were treated with conservative management, often called "watchful waiting."
Patients treated with androgen deprivation therapy - half of whom were treated for more than 30 months - had a lower 10-year, cancer-specific survival rate than those who underwent conservative management (80.1 percent vs. 82.6 percent) and equivalent 10-year overall survival rates. Androgen deprivation therapy did slightly improve cancer-specific survival at 10 years in men with poorly differentiated cancer, the authors noted, but there was no significant difference in overall survival in that patient subset.
"There have been more reports of health risks such as fractures, diabetes, heart disease, and other adverse effects associated with chronic use of this therapy," said the study's lead author, Dr. Grace L. Lu-Yao. "Therefore, it is imperative that more exploration is done on the appropriate application of this treatment."
Testing SNPs Improves Breast Cancer Risk Tool Modestly
In recent years, at least seven common genetic variants - single nucleotide polymorphisms, or SNPs - have been definitively linked to breast cancer. Researchers have begun to ask whether this knowledge can improve current tools for assessing breast cancer risk. The answer is yes, but only modestly, according to an analysis by Dr. Mitchell Gail of NCI's Division of Cancer Epidemiology and Genetics in today's Journal of the National Cancer Institute.
Dr. Gail led the team that developed NCI's Breast Cancer Risk Assessment Tool (BCRAT), which is based on questions about a woman's family and reproductive histories. The tool has helped women make decisions such as whether to take a drug to prevent breast cancer.
The new study found that a panel of seven SNPs was not as informative as the BCRAT in assessing a woman's breast cancer risk and therefore should not replace it as a screening tool. When the SNPs were combined with the BCRAT, they modestly improved the "discriminatory accuracy" of the BCRAT, which is the ability to distinguish women who will develop breast cancer from women who will not.
"These SNPs can improve the discriminatory accuracy of the BCRAT, but it is a small incremental change," Dr. Gail notes. "One would do better by asking women the questions [about their health and family histories] than by looking at these SNPs alone."
The SNPs, reported by two genome-wide association studies and a study of candidate genes, are located in FGFR2, TNRC9, MAP3K1, LSP1, CASP8, chromosomal region 8q, and chromosomal region 2q35.
Dr. Gail estimates that if many additional risk SNPs are identified, it could improve the risk prediction models substantially, but this will need to be evaluated once the true scope of genetic susceptibility factors for breast cancer are known.
Noninvasive Approach to Monitoring NSCLC Shows Promise
In a small study involving patients with metastatic non-small-cell lung cancer (NSCLC), researchers have shown that rare, circulating tumor cells (CTCs) in the blood can be molecularly analyzed before and after treatment to identify mutations that can affect treatment outcomes and influence decision making.
To conduct the study, published online June 2 in the New England Journal of Medicine (NEJM), researchers from Massachusetts General Hospital used an investigational CTC-chip device to capture the CTCs. They then used the Scorpion Amplification Refractory Mutation System (SARMS) assay to analyze the cells for mutations in the epidermal growth factor receptor (EGFR) gene that have been associated with response and eventual resistance to EGFR-targeted agents.
"Together with the CTC-chip, the SARMS assay may allow for noninvasive genotyping in patients with [NSCLC], which could then be repeated at therapeutic decision-making points during a patient's course of therapy," wrote study leader Dr. Shyamala Maheswaran and colleagues.
Using the CTC-chip, the researchers isolated CTCs in all 27 patients in the study in sufficient quantities and with sufficient purity for molecular analyses. So-called "activating" mutations in the EGFR gene were detected in the CTCs from all patients; a specific mutation that is associated with resistance to EGFR-targeted agents was detected in 55 percent of the 20 patients who had CTC and/or tumor and plasma specimens available for molecular analysis.
Reductions or increases in CTCs were associated with response to treatment and progression of disease, respectively, the authors wrote.
In the CTCs from several patients, they also identified the emergence of additional EGFR-activating mutations during treatment, which "we therefore presume… represents the emergence of different tumor clones," they wrote.
In a related NEJM commentary, Dr. Joan Schiller from the Harold C. Simmons Comprehensive Cancer Center in Texas said the study represents a proof of principle. "The ease with which this approach can be used by others remains to be determined," she wrote.
Glioblastoma Stem Cell Signature Identified
Researchers from the University of Lausanne have identified a "stem-cell like" gene signature associated with poorer survival outcomes in patients with glioblastoma treated with radiation therapy and temozolomide.
The researchers analyzed 80 tumors taken from patients in two other prospective clinical trials investigating glioblastoma (one phase II and one phase III trial), they reported in the June 20 Journal of Clinical Oncology. Patients whose tumors expressed a signature dominated by homeobox (HOX) genes, which play an important role in development, had outcomes nearly three times worse than patients without that signature.
The researchers suggest that the HOX signature belongs to a stem-cell-like phenotype that responds poorly to the temozolomide-radiotherapy regimen that has shown some success in treating glioblastoma. The results support the idea that tumors with the signature may include mutated self-renewing progenitor cells which give rise to malignant gliomas that are resistant to radiotherapy and chemotherapy, compared with other glioblastoma cells.
This work underlines "the need for multimodality treatments" aimed at the factors that determine outcomes in glioblastoma, the researchers suggest. Their data also show that tumors overexpressing the epidermal growth factor receptor gene conferred a comparably poor outcome, though this effect was independent of the HOX association.
"These findings provide the first clinical evidence to our knowledge for the relevance of a stem-like cell phenotype in treatment resistance of glioblastoma," the researchers write. The signature, they note, "is evocative of a self-renewal signature recently described for leukemia."
Yeast-Based Vaccine Triggers Immune Response in Mouse Models of Cancers
Researchers in NCI's Center for Cancer Research have tested a new approach for developing cancer immunotherapy; genetically engineering a harmless strain of yeast to produce a tumor protein called carcinoembryonic antigen (CEA) that triggers an immune response against certain types of cancer but not against healthy tissue. Their study results appeared July 1 in Clinical Cancer Research.
The scientists, led by Dr. Jeffrey Schlom, genetically engineered Saccharomyces cerevisiae, a strain of yeast that causes no disease in humans and has been used safely in other clinical trials, to express CEA, a surface protein that is normally expressed in the blood during fetal development but rarely appears again in healthy individuals. In patients with some carcinomas, however, CEA is overexpressed. Using mouse models for colon and pancreatic cancer types that were also engineered to express CEA, the researchers injected either the CEA-yeast vaccine or a control vaccine, a non-genetically engineered form of the yeast that was heat-killed prior to injection.
In mice that received the CEA-yeast vaccine, CD4+ and CD8+ T-cells responded to the stimulus and began to attack the tumors. Giving the vaccine as a series of injections (up to four times) increased the T-cell response. Higher vaccine doses and multiple injection sites also increased the response, which resulted in tumor shrinkage and increased overall survival. These results were also seen in a CEA-mouse-model in which tumors had metastasized to the lung. In all cases, the mice that received the CEA-yeast vaccine showed no toxicity or autoimmune disease.
S. cerevisiae is easy to genetically engineer and culture, it triggers a strong immune response, and it is safe. "All of these qualities make [it] an attractive vehicle for cancer immunotherapy," the authors conclude.
Enhancing the Training Experience at NCI
The importance of nurturing and developing the next generation of cancer researchers simply cannot be overstated. It is a priority that has universal support in the cancer community. The need, I believe, goes beyond replacing or maintaining the current oncology workforce; rather, there must be a very real emphasis placed on doubling this workforce over the next decade. These researchers are needed to translate and deliver on the promise of personalized oncology, working in cross-disciplinary teams and focusing on cancer as part of a biological system, rather than as a disease specific to a particular organ.
With that priority in mind, NCI is establishing the Center for Cancer Training (CCT) to coordinate the Institute's training programs, both intramural and extramural, across all areas of NCI's research. I have appointed Dr. Jonathan Wiest to lead a confederation of training programs that will work across the spectrum of trainees from high school students to researchers and clinician scientists with advanced degrees. A recognized visionary and strong leader of cancer career development programs, Dr. Wiest has, for the past 7 years, been responsible for training in NCI's Center for Cancer Research.
Working alongside NCI training officers, Dr. Wiest will be taking a critical look at scientific discovery in the 21st century, in order to anticipate the future training needs of biomedical researchers. Those requirements may very well change over time, as collaborations across diverse technologies - including mathematics, physics, and engineering - will be essential to future successes in cancer research.
In the near term, CCT will bring together training programs currently housed across NCI divisions, offices, and centers, in order to align programs, streamline operations, improve efficiencies, enhance communication, and identify and implement best practices across NCI's entire research portfolio. This critically important ability is an extension of some of today's successful training efforts. For example, the Joint-Fellowship Program launched by the NCI-FDA Interagency Oncology Task Force enables cancer researchers to gain greater understanding of the regulatory review process. Another important initiative, the Cancer Prevention Fellowship Program trains postdoctoral candidates in the conduct of research in cancer prevention and control.
CCT will also take advantage of NCI's intramural resources, such as career development courses and individual training plans. The goal is to create a coordinated cancer training enterprise that retains the unique missions and resources of each existing program.
I am confident that coordinating intramural and extramural training through the CCT will synergize existing programs and help us foster a dedicated cancer research workforce for the future.
Dr. John E. Niederhuber
For related information, please visit the resources page from our special issue on NCI training.
FY08 Supplement Signed; FY09 Appropriations Bill Still Pending
On June 30, President George W. Bush signed H.R. 2642, the Supplemental Appropriations Act of 2008, into law (P.L. 110-252). The bill provides funding for another year of military operations in Iraq and Afghanistan but also provides $24.7 billion for domestic programs, including $150 million for NIH. Of that, NCI will receive $25 million.
Both the U.S. House of Representatives and the U.S. Senate have introduced fiscal year (FY) 2009 appropriations bills for the Departments of Labor, Health and Human Services, and Education that exceed President Bush's budget request. The Labor-HHS-Education appropriations bill, approved by the Senate Appropriations Committee on June 26, would provide $153.1 billion in discretionary spending - $8 billion more than in FY2008 and $7.7 billion more than the President requested for the agencies it covers. President Bush has threatened to veto any spending bill that exceeds his budget. The House version of the Labor-HHS-Education appropriations was scheduled to be marked-up on June 26 but was postponed until after the July 4 recess.Both the House and the Senate versions of the Labor-HHS-Education bill emphasize funding for NIH. The Senate bill provides NIH about $30 billion, a $1 billion increase. The House bill would provide $30.1 billion.
Some Exercise a Day May Keep Cancer at Bay
The observations were compelling, to say the least. First it was breast cancer, then colorectal cancer: 40 to 50 percent reductions in the risk of cancer-related death and cancer recurrence.
The apparent cause was not a new targeted agent or a novel combination therapy, but rather, frequent trips back and forth in heavily chlorinated water, regular bouts with yard mulch and garden weeds, striding through the neighborhood for 30 minutes every morning. In other words, old-fashioned exercise.
Five large observational studies have now linked reports of regular post-treatment physical activity with superior outcomes compared with patients who remained sedentary after treatment. And now the first prospective, randomized clinical trial is nearly set to test whether physical activity can indeed influence cancer's course after treatment.
Results from the observational studies "are certainly compelling enough to warrant a randomized trial of physical activity," says Dr. Kerry Courneya, of the University of Alberta, who will lead the trial in patients who have been treated for colon cancer.
The trial represents a shift of sorts, because most cancer-related physical activity research to this point has not focused on recurrence or survival.
The level of activity required for a measurable benefit varied, but the cancer mortality risk reductions reported from the large observational studies of physical activity - two of which came from the long-running Nurses' Health Study - have been fairly consistent.
"It's certainly intriguing data," says Dr. Wendy Demark-Wahnefried, from the Department of Behavioral Science at the University of Texas M.D. Anderson Cancer Center, who has been studying the impact of diet and exercise on long-term cancer survivors for more than a decade. "One of the questions now is whether the clinical trials [of physical activity] can be done, because I think there is tremendous interest."
NCI sponsored a workshop 2 years ago on how best to design such trials, notes Dr. Ballard-Barbash, and NCI has been fielding proposals to conduct them.
Dr. Lee W. Jones, director of the Tug McGraw Research Center at the Duke University Medical Center, says data to help inform optimal trial design (e.g., type of activity, intervention delivery strategies, etc.) is coming, as well as data on the potential biological mechanisms by which exercise may inhibit tumor growth.
Researchers, Dr. Jones says, have speculated that physical activity might influence post-treatment outcomes in breast cancer patients by dampening levels of estrogen or insulin, elevated levels of which are associated with poor outcomes. Several studies involving breast cancer patients, for instance, have consistently found a threefold increased risk of death among women with the highest insulin levels.
Meanwhile, studies involving patients with a range of problems, including diabetes and heart disease, have shown that physical activity can reduce insulin levels. Last year, researchers from Dana-Farber Cancer Institute (DFCI), led by Dr. Jennifer Ligibel, showed that a regimen of cardiovascular and strength training lowered insulin levels in sedentary women who had completed adjuvant therapy for early stage breast cancer.
"We're very interested in what happens biologically with physical activity," explains Dr. Ligibel, from DFCI's Breast Cancer Program. "We think it has to be modification of hormone levels.…And the data suggest that estrogen is not the whole story."
The data, however, are far from consistent.
"In our preclinical studies, we've found that the hypoxia/angiogenic pathways are really upregulated with exercise, but that insulin doesn't change much," says Dr. Jones. (This does not necessarily mean that exercise doesn't alter insulin signaling in the tumor, he cautions.) And in one animal model study of prostate cancer, Dr. Jones adds, voluntary exercise actually accelerated tumor growth.
The trial Dr. Courneya is leading, dubbed CHALLENGE, is set to launch by the end of this year in Canada, and will investigate whether increased physical activity can improve disease-free survival (DFS) in patients treated for high-risk stage II and III colon cancer. (Another Canadian clinical trial that is already underway, called LISA, is testing whether a dietary and physical activity regimen focused on weight loss can improve DFS in overweight or obese women who have been treated for early stage breast cancer.)
The physical activity intervention in the trial follows from a similar - and highly successful - trial, the Diabetes Prevention Program.
"The activity in this trial will be a mix," Dr. Courneya explains. "The literature doesn't point to a specific type of exercise that has the most benefit. So we're going to promote aerobic exercise, assuming that most participants will walk, but expecting that others will do things like biking or swimming."
The physical activity component will include in-person or phone-based meetings with exercise consultants for 3 years, with more frequent meetings for the first year.
"This isn't like taking a drug," Dr. Courneya acknowledges. "These types of lifestyle interventions are difficult and have to be delivered over a longer period of time."
Dr. Ligibel agrees that delivery of the intervention is a challenge.
"The data suggest there is better compliance with dietary modifications than physical activity modifications," she says.
Even so, small studies and trials of the influence of exercise on cancer outcomes are multiplying and expanding to other cancer types. Dr. Jones' group at Duke, for example, has been conducting studies in patients before and after lung cancer surgery, as well as in patients with primary brain tumors.
"I'm very confident that anybody, regardless of where they are in the cancer survivorship continuum, can exercise," Dr. Jones says. "It's just a matter of what type of exercise, the frequency, and the intensity."
—Carmen Phillips
FDA Still Considering Gardasil Use in Older Women
The HPV vaccine Gardasil is not yet approved for women aged 27 to 45, according to a "complete response" letter to the vaccine's manufacturer, Merck & Co., from the Food and Drug Administration (FDA). The FDA wrote that its review of the company's supplemental biologics license application (sBLA) to add women 27 to 45 as an approved indication is complete, but that the vaccine will not be approved within the 6-month "priority review" period due to issues with the submission.
Merck expects to submit its responses this month, the company noted in a statement. Gardasil is already approved for use in females aged 9 to 26 for the prevention of HPV 6, 11, 16, and 18 infection.
The sBLA was based on data from a study of 3,800 women aged 24 to 45, who were free from infection by at least one of the four HPV types covered by the vaccine. Gardasil prevented 91 percent of persistent HPV infections, low-grade cervical abnormalities, and precancers caused by one of those four HPV types compared with women given placebo. The prevention rate for those endpoints was 83 percent when the analysis was limited to HPV types 16 and 18, which are responsible for approximately 70 percent of cervical cancer cases.
The FDA issued a second complete response letter to Merck regarding an sBLA to market Gardasil as "cross-protection" against HPV types not specifically covered by the vaccine.
"According to the FDA, the data submitted do not support extending the indication for Gardasil to include nonvaccine HPV types," Merck said.
HER2 Test for Breast Cancer Approved
A genetic test that can help identify women with breast cancer who are candidates for the drug trastuzumab (Herceptin) was approved by the FDA today. The test measures the number of copies of the gene HER2 in tumor tissue; women with extra copies of this gene may benefit from trastuzumab.
The SPOT-Light HER2 CISH kit involves staining a small sample of tumor tissue. The stain causes tissue with extra copies of HER2 to change color. "The color change can be visualized under a standard microscope, eliminating the need for the more expensive and complex fluorescent microscope," according to a statement by the FDA.
Unlike existing tests, the SPOT-Light, which is manufactured by Invitrogen Corp., allows labs to store the tissue for future reference, the FDA said.
New Drugs for Multiple Myeloma Consolidation Therapy
Name of the Trial
Principal Investigator
Why This Trial Is Important
Patients with multiple myeloma are often treated first with chemotherapy drugs and the steroid dexamethasone to induce remission (induction therapy). This is often followed by "consolidation therapy" with high-dose chemotherapy and stem cell transplantation. Although consolidation therapy has produced longer survival, the side effects associated with it can be severe and may dramatically affect quality of life. Doctors want to study new consolidation therapy options, using recently developed drugs, to see if they can achieve the same or better outcomes without as much risk to the patient.
In this trial, newly diagnosed patients who have undergone induction therapy will be treated with consolidation therapy consisting of dexamethasone and the drug bortezomib. Some patients will also be randomly assigned to receive a third drug called lenalidomide. Both bortezomib and lenalidomide have been approved by the FDA to treat patients with relapsed multiple myeloma, and they have shown promise in early clinical trials involving patients with newly diagnosed disease.
"One of the biggest questions in the minds of patients in this era of new drugs is, 'Do we still need to have a transplant?'" said Dr. Rajkumar. "Autologous transplants are associated with significant morbidity and can be life changing. Both of these regimens hold the promise of high response rates that may rival what we can achieve with stem cell transplantation while being easier on patients."
For More Information
An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.
DCTD's Sheila Taube Retires
Under Dr. Taube's guidance, CDP created the Program for the Assessment of Clinical Cancer Tests (PACCT) to translate new knowledge and technology related to cancer diagnosis into clinical practice. As part of PACCT, the first prospective trial using a molecular signature for risk of recurrence to guide treatment decisions in early stage breast cancer, the Trial Assigning IndividuaLized Options for Treatment (TAILORx), opened in 2006.
Dr. James Jacobson will act as the CDP associate director. Dr. Jacobson is chief of the Diagnostic Biomarkers and Technology Branch in CDP.
caBIG Annual Meeting Widely Attended
The meeting program, materials from the plenary presentations, and a meeting summary are available at https://cabig.nci.nih.gov.
BSA Meeting Held
Community Cancer Centers Program Begins Year 2 with National Meeting
Following are newly released NCI research funding opportunities:
Collaborations with National Centers for Biomedical Computing
Application Receipt Date/Dates: Non-AIDS Applications (new): Oct. 5, 2008; Feb. 5, June 5, and Oct. 5, 2009; Feb. 5, June 5, and Oct. 5, 2010; Feb. 5, June 5, 2011.
This is a renewal of PAR-07-249 and will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3894. Inquiries: Dr. Jennifer Couch - email@example.com.
Collaborations with National Centers for Biomedical Computing
Application Receipt Date/Dates: Non-AIDS Applications (new): Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, June 16, 2011.
This is a renewal of PAR-07-250 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3894. Inquiries: Dr. Jennifer Couch - email@example.com.
Exploratory/Developmental Grant for Complementary and Alternative Medicine Studies Using Cells, Tissues, and Animal Models of Disease
Application Receipt Date/Dates: Non-AIDS Applications (new): Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011, June 16, 2011.
This is a renewal of PA-06-315 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3892. Inquiries: Dr. Cindy D. Davis - firstname.lastname@example.com.
Mechanisms of Immune Modulation
Application Receipt Date: Oct. 17, 2008.
This is a renewal of RFA-AT-07-004 and will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3893. Inquiries: Dr. Young S. Kim - email@example.com.
Mechanisms of Immune Modulation
Application Receipt Date: Oct. 17, 2008.
This is a renewal of RFA-AT-07-005 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3893. Inquiries: Dr. Young S. Kim - email@example.com.
Improving Effectiveness of Smoking Cessation Interventions and Programs in Low Income Adult Populations
Letter of Intent Receipt Date: Oct. 24, 2008.
This funding opportunity will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3895. Inquiries: Dr. Erik Augustson - email@example.com.
Improving Effectiveness of Smoking Cessation Interventions and Programs in Low Income Adult Populations
Letter of Intent Receipt Date: Oct. 24, 2008.
This funding opportunity will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3895. Inquiries: Dr. Erik Augustson - firstname.lastname@example.com.
Dr. Tom Misteli
Senior Investigator, Center for Cancer Research, NCI
Dr. Tom Misteli had no intentions of becoming a scientist when he grew up in a small town near Berne, Switzerland.
"I wasn't one of those kids running around saying, 'I'm going to be a doctor.' I was interested in lots of different things," he explains. "After high school I was torn between studying literature and biology. Then, one day, I was on a train trip, and I bought a copy of Scientific American for whatever reason - it was a special issue on molecular biology - and it absolutely captured my attention. That's how I decided I was going to be a biologist.
"I remember my father asking me 'Are you sure about this?' And I said, 'Not at all, but I'm going to see whether I like it,'" he laughs.
Today, Dr. Misteli remains a committed cell biologist, heading the Cell Biology of Genomes Group in the Laboratory of Receptor Biology and Gene Expression in NCI's Center for Cancer Research, where he focuses on an unusual niche in molecular research: How the spatial organization of the genome within a cell's nucleus contributes to cell functioning and to the origins of disease.
After earning his Ph.D. from the University of London and the Imperial Cancer Research Fund, London, Dr. Misteli worked as a postdoctoral fellow at Cold Spring Harbor Laboratory in New York, where he became interested in genome organization.
"This is an area of research that 5 or 6 years ago, literally nobody in the United States worked on because it was extremely high risk," says Dr. Misteli. That is, few other researchers had explored this area of cell biology, leaving a gap in the scientific literature that made it difficult to justify a project on the neglected subject. "I came to NCI because it provided a lot of freedom to do high-risk research, which is increasingly more difficult in the outside [research] world."
Dr. Misteli's lab uses molecular techniques including polymerase chain reaction and microarrays to measure gene expression, in addition to time-lapse microscopic techniques that visualize the movement of gene loci in single living cells.
All but one of the genes they observed undergoing repositioning during early tumor differentiation also moved during normal differentiation, but several additional genes - including genes known to drive cancer development - also changed their location within the nucleus in the tumor model. Dr. Misteli's group is now exploring these positional changes of tumor genes for diagnostic purposes.
Other recent work from the lab has shown how the proteins that repair damaged DNA physically interact with the chromosomes, and how the mutant protein responsible for Hutchinson-Gilford Progeria Syndrome - a premature aging disease - interferes with the functioning of stem cells that produce the bones, blood vessels, connective tissues, and other vital structures of the body. The next step in this field with regards to cancer, explains Dr. Misteli, is to discover the mechanisms by which higher order genome organization helps drive the process of tumorigenesis.
"We're at a point where we now understand the fundamental concepts, the fundamental principles by which genomes are organized in the nucleus, and I would argue, even the principles by which genomes function," he says. "So the next step is to link some of these morphological observations to function, to physiology, and to disease."


text:
Duration: 20 minutes
Drama series about parents, their children and their children's minder. Sampson stops a child from running out onto the road, and Dr Juno is very proud of him.
BBC © 2014 The BBC is not responsible for the content of external sites. Read more.
This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.


text:
Distance Learning
Online & Hybrid Online
- Fully online classes. Take classes using a computer with an internet connection anywhere.
- Hybrid online classes. Complete a portion of the class using a computer with an internet connection anywhere and come to campus for class meetings. Some classes have mandatory on-campus orientations.
Online and Hybrid online classes are not self-paced. Students participate in regular and substanative contact with the instructor. Class assignments, quizzes and exams have deadlines, and the class follows the regular semester schedule. All online classes use CCSF's learning management system, Insight.
A combination of videos, textbook readings, written assignments and phone contact.
There are three mandatory on-campus sessions: an orientation, a midterm, and a final exam.
Videos are available to watch in several ways:
- Cable Channels 27 and 75 broadcast in San Francisco
- The Media Center in Rosenberg 403 on the Ocean Campus
- Purchase and View Streaming Telecourse Videos


text:
The Spokane Shock return to the Arena tonight to face the Utah Blaze. The game will be live on SWX (Comcast channel 115) at 7:00 p.m. and the replay will be Saturday at 2:30 p.m.
Here is the official preview and game notes from the Shock.
SPOKANE, WA (June 18, 2013) - The Spokane Shock will return home to square off with the last-placed Utah Blaze on Friday, June 21 at 7 p.m. at the Spokane Veterans Memorial Arena.
Spokane (9-4, 3-2) is looking to bounce back from a tough 42-59 loss last Saturday against division foe Arizona Rattlers (12-1, 4-1). Spokane was undone by a rough stretch early in the fourth quarter in which the Shock, down 35-45, missed a field goal helping set-up a short Arizona touchdown, and then turned the ball over on downs, which led to another short Rattler's touchdown to give Arizona a 59-35 lead, which they would not relinquish.
Shock quarterback Erik Meyer completed 29-of-43 attempts for 256 yards and five touchdowns and one interception in the loss. Wide receiver Adron Tennell hauled in new franchise single-season record 15 receptions for 110 yards and four touchdowns while Brandon Thompkins caught nine balls for 111 yards.
The Shock will look to get back on track against the Blaze and try to separate themselves from the San Jose SaberCats who climbed to within a half-game of the Shock for second in the National Conference-West Division with five games remaining in the regular season.
Although the Blaze sit in last place in the West Division standings with a 5-7 record, Utah has proven to be a tough matchup for Spokane winning the last three games against the Shock dating back to last season.
Game notes:
Former starter and current Blaze backup quarterback Tommy Grady torched Spokane for 366 yards and 9 TDs in a 58-55 victory back in June 2012 and enjoyed similar success earlier this season completing 26-of-39 attempts for 329 yards and seven touchdowns in a thrilling 52-48 victory at EnergySolutions Arena in Salt Lake City, Utah.
The game came down to the final play as the Blaze were able to stave off four consecutive Shock attempts from inside the 10 yard line to preserve the victory. Utah's Mario Urrutia led the Blaze offensive attack with 11 receptions for 122 yards and three touchdowns while Caesar Rayford forced one of his league leading four fumbles against Meyer. Meyer struggled on the night completing 26-of-39 passes for 276 yards and three touchdowns while Kamar Jorden led the Shock receiving effort with 10 receptions for 112 yards.
The Blaze are also coming into Fridays matchup with some momentum after pulling off a 62-55 upset win against the American Conference-leading Jacksonville Sharks (8-5) last Saturday night in Utah.
Quarterback Jason Boltus threw for 240 yards and seven touchdowns while adding 31 yards and a rushing score in the first start of his Arena Football League career. Boltus appeared in one game last season with the Spokane Shock, going 4-6 for 30 yards. Against the Sharks he hooked up with wide receiver Braylon Bell six times for 120 yards and three touchdowns while Urrutia reeled in eight catches for 62 yards and two touchdowns.
Utah's defense came up big in the win manufacturing four stops on the night including interceptions from linebacker Tony Tatum and defensive back David Hyland, who collected his franchise record sixth interception in 2013.
Led by Hyland, the Blaze boast the league's third ranked pass defense only giving up 239.2 yards per game and also are third in the AFL in total defense allowing only 259 total yards per game.
Although Grady is currently fifth in the league in passing yards throwing for 268.3 yards per game, Boltus's strong performance has once again thrust his name into the starting conversation for Saturday's game. Whoever is under center for the Blaze will lead an offense that is currently third in the league with 277.5 passing yards per game and fourth in the league in total offense racking up 294.1 yards per game. The Blaze love to control the tempo of the game and currently lead the AFL in time of possession holding on to the football for a little more than 33 minutes per contest.
This week's game will be broadcast live on SWX-TV, available for listening pleasure on 700 AM ESPN and online at shock.arenafootball.com/allaccess. Tickets are still available and can be purchased via TicketsWest using the promo code 'SHOCKHUNGER,' which will help fight hunger in the Inland Northwest community by sending net proceeds to Second Harvest Inland Northwest and Post Falls Food Bank. Fans are also encouraged to bring non-perishable food items to the Spokane Arena, and for donations made, fans will receive a special food related coupon courtesy of our premiere partners.


text:
The classic solitaire pendant is updated with a romantic heart-shaped gemstone. See Details
Gemvara jewelry is truly personal: you design it, choosing gems and metals to celebrate your story, and we craft it just for you. We'd love to help you find your perfect piece! (more)What quality are your gemstones?
They are all-natural and hand selected fine quality. (more)


text:
Follow us:
Click below to filter your search results
Number 471
(Reaffirmed 2013, Replaces No. 316, October 2005)
ABSTRACT: Smoking is the one of the most important modifiable causes of poor pregnancy outcomes in the United States, and is associated with maternal, fetal, and infant morbidity and mortality. The p...
November 2010
American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC 20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998
Copyright Terms of Use


text:
Showing 1 - 1 of 1 Product
Model: 282 |
Catalog #: 55054654
Dungeons Gold includes the fantastic strategy best-seller Dungeons in its comprehensive Game-of-the-...
See the Full Product Details
Online prices and product selection may vary from our retail stores. All prices and offers are subject to change. Copyright RadioShack Corporation 2014. All rights reserved.


text:
Alder Creek New Baby Spa Gift Tray
by Alder Creek | Item #: 393438 |Model #: FG06485 | (3) |
For the New mom, our extra large serving tray arrives overflowing with nourishing Lauren Nichole green tea scented spa products.
Included in this gift is our luxurious bath cream, shower gel, bubble bath and body lotion. To finish off this heavenly gift, we have added a natural bath mitt and a frosted "New Baby" cookie and packages it together in a reusable faux leather serving tray!
Assembled Country
Component Country
Ask & Answer
Warranty InformationThis product is covered by the Sam's Club Member Satisfaction Guarantee.
There is no additional information available for this item.


text:
These Cognacs have been specially blended to match perfectly with a good cigar.
There is a long tradition of marrying cigars and sipping Cognac. A good Havana -even a relatively modest Romeo y Julieta or a Montecristo- will enhance enormously the Cognac experience of a cigar smoker. While smoking cigarettes while sipping a good Cognac may, acording to many experts, reduce drastically the tasting ability, paused and calm cigar smoking seems in many cases to interact powerfully and increase the array of tastes (perhaps more than the aromas) and become a radically pleasant experience.
Gautier - Pinar del Rio XO
An exceptional Cognac, blended with eau de vie aged up to 25 years. For the connoisseur who will appreciate the marriage of aged Cognacs with quality cigars. A real achievement !Learn MoreExcl. Tax: €70.83 Incl. Tax: €85.00


text:
The New York Yankees will take on cadets from the U.S. Military Academy at West Point, N.Y., in an exhibition game this spring, MLB.com reported.
The Bombers will play Army at 2 p.m. on March 30, 2013, Major League Baseball announced.
West Point and the Yankees have had a long relationship.
Army has played college football games at Yankee Stadium, in 1982 the Yankees conducted preseason workouts on campus, and the boys in pinstripes played exhibition games at West Point back in the Ruth-Gehrig era, MLB.com reported.


text:
Shop Our Store
More Ways To Shop
More Ways To Save
Select your preferred location and we'll note which parts are ready to be picked up TODAY.
Image is a representation of this item.
Actual item may vary.
Carpet, Black, Cut Pile, Buick, Chevy, Oldsmobile, Pontiac, G-Body, Kit
Order this item and get free delivery and handling on your entire order! Offer excludes truck freight fees. Valid on orders shipped in the contiguous United States.
Estimated Ship Date: Today Would you rather pick it up? Select Location
View Similar Products
Better than OEM carpet, these pre-formed Trim Parts carpet kits are made to OEM specifications and come in two different types--80/20 loop carpeting for 1950s-1970s vehicles and 16 oz. cut pile for most classic and late model vehicles. To make installation a snap, you get dimmer switch grommets, heel pads, and thick 40 oz. padding, along with a handy set of instructions.
Average Customer Review
5 Star
4 Star
3 Star
2 Star
1 Star
Summit Racing Verified Purchase
1 of 1 found this review helpful.
Was this review helpful?
Reviewer: JOHN from PA
Date: July 15, 2014
Summit Racing Verified Purchase
0 of 0 found this review helpful.
Was this review helpful?
Reviewer: STAN from VT
Date: August 19, 2014
Some parts are not legal for sale or use in California on any pollution-controlled motor vehiclesBack To Results


text:
This was inspired by a picture on Stephen Cooks blog. I was sitting here, wondering what to make for dinner when I came accross his pic of the corn salad. I had leftover grilled veggies I needed to use immediately, so I tossed those with some blanched corn, carrots, edename, fresh rosemary, thyme, and chives, and mustard vinaigrette, then topped it off with some grey celtic sea salt and ground chipotle pepper. Delicous. I have some leftovers too. You know, if it was cool outside, I'd toss this with potatoes and some cashew milk for a nice veggie chowder. I'll probably mix this in with some pasta and creamy pesto sauce for a pasta salad later on today. That will be good.
I'm thrilled to report that my oldest son LOVES my new seitan. (post before this) I admit, I lied and told him I made it all out of soyflour and it is kind of like homemade tofu. I haven't cooked it in a dish yet, I just gave him a piece of the teryaki marinated seitan. I know he'll love a grilled teryaki sandwich with it. Woohoo! This makes me very happy.


text:
Top Rated
Hydrating TonerBalances, refreshes and neutralizes impurities$27.006.0 FL. OZ.259 Reviews
Top Rated
*Individual results will vary. Free shipping offer valid on standard shipping for U.S. orders only. Free gift offer valid through 6/19/2014 or while supplies last. Connot be combined with any other offer. Murad Terms and Conditions apply.


text:
Publication: theday.com
Gov. Dannel P. Malloy and members of the congressional delegation hailed the president's new proposals for curbing gun violence as common sense steps that could prevent another tragedy like the Newtown school shooting.
President Barack Obama and Vice President Joseph Biden unveiled a plan Wednesday to require criminal background checks for all gun sales while banning military-style assault weapons and high-capacity magazines and improving access to mental health services.
They want to put up to 1,000 more resource officers and counselors in schools and help schools develop emergency management plans. Twenty-six staff and students were killed Dec. 14 at Sandy Hook Elementary School.
In the midst of the grief and sorrow over the loss, Malloy said, "There was one question on the minds of people across Connecticut and around the nation — how do we make sure this never happens again?
"Today the president took the critical first step toward answering that question," he said in a statement. "The common sense measures he proposed today are something that we should all be able to agree on."
Malloy said that in the months ahead, he will try to make sure Connecticut is a national leader in preventing gun violence. Malloy has created an advisory commission and on Tuesday, state lawmakers created a Gun Violence Prevention and Children's Safety Task Force.
State Senate President Pro Tempore Don Williams, D-Brooklyn, and Senate Majority Leader Martin M. Looney, D-New Haven, issued statements Wednesday praising the White House for taking action, and emphasizing the importance of reducing gun violence, increasing access to mental health services and improving school security at the state level.
Obama signed executive orders to put 23 of the measures into place and called on Congress to require a background check for anyone trying to buy a gun as well as a ban on assault weapons and high-capacity magazines. Obama also said he would seek confirmation for B. Todd Jones as director of the Bureau of Alcohol, Tobacco, Firearms and Explosives. Jones is the bureau's acting director.
U.S. Rep. Joe Courtney, D-2nd District, said Obama "set the ball in motion" with his ideas on how to make school districts safer and stop guns from getting into the hands of criminals and the mentally ill, while preserving the Second Amendment rights of law-abiding citizens.
Connecticut's U.S. Sens. Richard Blumenthal and Chris Murphy said Congress should act on these changes to make the nation safer.
Blumenthal has drafted a bill to require background checks on people buying gun ammunition. He called the president's plan "a blueprint to seize this moment," keep faith with the victims of recent tragedies and sustain the momentum.
Murphy said that if assault weapons and high-capacity magazines were not so readily available, "there would be more little boys and girls alive in Newtown today."
"There are no longer any excuses for inaction," Murphy said. "If the horror of Sandy Hook doesn't move Congress to act on common sense gun laws, I have no idea what will."
Tri-Town iPad mini ContestEnter for a chance to win an iPad mini
Flat StanleySubmit your Flat Stanley photos for a chance to win!
40 Under Forty 2014Nominate a deserving professional in our region for recognition in our special section.
Connecticut Family Magazine Fall 2014Tell us your favorite children's books, board games, and more. You might be featured in an upcoming issue.
Pro FootballPredict pro football winners each week for a chance at local and national prizes, including a trip to Hawaii.
Photo Calendar ContestSubmit your photos for Southeastern Connecticut for our very popular annual calendar.
Freaky FridaysEnter now! We're giving out 13 trick-or-treat bags full of goodies every Friday from Sept. 26 through Oct. 17.
Will you watch Oprah's interview Thursday with disgraced Tour de France champion Lance Armstrong?
No current items found


text:
Enlarge / Alternate Images
Clinical Kinesio® Taping Application - DVD
In this video certified Kinesio® Taping Instructor Jim Wallis, MS, ATC will take the practitioner step by step in proper application of the Kinesio® Taping techniques. From the lymphatic functions to the analgesic effects of the taping system, it is easy to recognize the many benefits possible for your patients. This DVD includes concepts, applications and several taping techniques.This modality works on a therapeutic basis 24hrs/day and for 3 - 4 days per treatment. Now there is no such thing as "off" treatment time. 45 minutes.


text:
Click here for the entire Purchasing Polices and Procedures Manual
|Effective Date:
|July 01, 2012
|Issuing Authority:
|Vice President for Administration
|Responsible Officer:
|Assistant Vice President
|Office Name:
|Purchasing Services and Contract Admin.
This Policies and Procedures Manual has been prepared to provide information about the University's purchasing requirements and Purchasing Services. Its various sections address the responsibilities ofthe Requisitioner, the Procurement Officer, and the Recipient of purchased products and services.The procedures also cover the use of i-Buy, Purchasing Card ($2500 limit) and Low Dollar Orders ($2500 limit), all decentralized systems for handling low-dollar purchases. i-Buy is an electronic marketplace that integrates with Purchasing Services' e-Requisitioning System to provide an on-line shopping experience with selected NYU suppliers.


text:
X-Hose Pro®
Reversible Bedspread
Singing Bird Clock & Thermometer
Set/2 Drawer Dividers
RFID Armored Wallets
Hot Air Balloon Spinner
Ribbon Braid Hat
Magnetic Board
Stay-Fresh Pie Keeper is a baker's best friend! See-through, crush-proof container snaps tight to keep your creations "right out of the oven" fresh. Holds 9"-diameter pie in its baking dish so that you can transport or store without disturbing even a flake! Deep dish (3½" deep) easily accommodates cream pies and meringues. Flat top allows for stacking. 11½"-diameter. Dishwasher safe plastic.
Forgot your password?
Try our Password Recovery Page.
Follow Fresh Finds!
Copyright 2014. Fresh Finds, LLC /
All Rights Reserved. Privacy Policy
Message from Fresh Finds
Fresh Finds
We are now accepting PayPal as a form of payment. For those of you unfamiliar
with PayPal, it is a Web-based service that enables you to pay an online
merchant without revealing your financial information. We've added this payment
option to better meet your expressed needs for confidence, control, convenience
and choice in your payment methods.
Learn more
about PayPal and decide if you would like to set up a PayPal account.
Thanks for visiting our Web site - come back soon!
Close Window


text:
StartUpHire is the place to find Developer jobs in and near Falls Church. Review the list of Developer Falls Church career opportunities to the left. These Developer jobs represent some of the most rewarding careers available.
You can refine your job search for Developer career opportunities in Falls Church by adding a job title, company name, or keyword to the search box above … or click the "Advanced Search" link for more options.
Don't see the employment opportunity you're looking for? Check back soon for more Developer jobs in Falls Church, or sign up for an email alert (link below) to receive periodic updates on new Developer jobs in Falls Church, VA.
Demand for Developer Professionals in Falls Church, VA
Developer Jobs in Minneapolis, MN
Job Description: Our ideal candidate must have solid experience developing large-scale high-traffic web-based applications. We-re looking for a self-motivated, innovative problem solver who makes the things happen. Experience is important but equally valuable is the ability to8/11/2014 Reston, VA Save This Job
Join a fast-growing Agile team of Software Developers and QA Engineers to build a world-class, high-volume software-as-a-service product. The Senior Front End Developer will work with our team to deliver a great front-end user experience both on web browsers and mobile9/24/2014 Annapolis, MD Save This Job
Application Developer, Clinical Research Systems Job Department: Clinical Research Systems Job Reports To: Senior Manager, Clinical Research Systems Position Summary The Application Developer has responsibility for development and support of critical applications within the8/12/2014 Rockville, MD Save This Job
Location : Baltimore MD US 21235 % of Travel Required : None Job Type : Full Time Shift/Hours : First Shift (Day) Career Level : Experienced (Non-Manager) Education : Bachelor's Degree Skill : Customer Service -> Frontline Support Graphics/Design -> Graphic Design, 4-color Print9/15/2014 Baltimore, MD Save This Job
Description MAJOR DUTIES AND RESPONSIBILITIES Report to the Director of IT and work with the requirements, design and development teams to develop and implement new applications as well as enhance existing proprietary websites, workflow systems, company and customer facing web8/28/2014 Lanham, MD Save This Job
Job Department: Clinical Research Systems Job Reports To: Senior Manager, Clinical Research Systems Position Summary The Senior Application Developer has responsibility for development and support of critical applications within the portfolio of third-party and8/12/2014 Rockville, MD Save This Job
Location: Washington, DCDepartment: iOS DevelopmentType: Full TimeMin. Experience: Mid Level About Flat World: Flat World is an education technology company revolutionizing how the world learns. Through our innovative education-as-a-service platform and digital-first textbook9/16/2014 Washington, DC Save This Job
Location : Baltimore MD US 21235 % of Travel Required : None Job Type : Full Time Shift/Hours : First Shift (Day) Career Level : Experienced (Non-Manager) Education : Bachelor's Degree Skill : Web Development -> Content Maintenance, DHTML, Dreamweaver, FrontPage, HomeSite, HTML,9/15/2014 Baltimore, MD Save This Job
Do you have a passion for IOS development? Are you a creative thinker who has a passion for building a compelling mobile experience using cutting edge technologies? Our Washington DC office is looking for an IOS Application Developer to work in mPortal?s innovation group. You9/10/2014 McLean, VA Save This Job
Department: Engineering Type: Full Time Min. Experience: 2+ Years We?re actively seeking a well-rounded front-end developer who can jump in and build pages and applications seen by millions of people every day. You should be able to build out the gorgeous designs of our8/30/2014 Silver Spring, MD Save This Job
Department: Engineering Type: Full Time Are you interested in building products used by millions of people? Do you wish you could launch code daily? Webs is looking for a talented Java developer that is passionate about building user-facing web applications. This position is8/30/2014 Silver Spring, MD Save This Job
Parabon Computation, a leading enterprise computing software company based in Reston, VA, seeks a software developer with the following qualifications: Required qualifications 3 Years of GWT GUI development (SmartGWT, GXT, or GWTEXT) At least three (3) years experience working8/19/2014 Reston, VA Save This Job
Job Description: Razorsight has an immediate need for a Senior ETL Developer with deep experience on the Microsoft BI stack. Candidates must have hands on expertise designing high volume repeatable ETL processes for large enterprise software and SaaS solutions developing very8/11/2014 Reston, VA Save This Job
The Senior MicroStrategy developer will be responsible for diagnosing and solving complex analytical issues in a fast paced environment. To succeed in this position , the candidate must be proficient with MicroStrategy (Desktop and Web), self-motivated, collaborative, and ever8/3/2014 McLean, VA Save This Job
We're looking for an Android developer to help us bring our award-winning real estate apps, including HomeSnap, to Android devices. The ideal person will have extensive Android development experience with in-depth knowledge of the Android SDK and related APIs. This person will be7/29/2014 Washington, DC Save This Job
We?re looking for an object-oriented developer who takes pride in building innovative, scalable applications in pursuit of a great user experience. You'll join the talented team that designs, develops, implements and maintains Sawbuck?s award-winning web and mobile applications.7/29/2014 Washington, DC Save This Job
We're looking for an iOS developer to help us improve and expand our iPhone and iPad apps, including our critically-acclaimed HomeSnap app. The ideal person is an Xcode expert with deep knowledge of many iOS frameworks, including: UIKit, MapKit, CoreMotion, CoreLocation and7/29/2014 Washington, DC Save This Job
We?re looking for skilled web designer/developer who takes pride in turning a great design into a great user experience. You'll join the talented team that designs, develops, implements and iterates Sawbuck?s award-winning web apps. If you know how to code HTML, CSS, and7/29/2014 Washington, DC Save This Job
We are currently looking for talented senior developers who are passionate about software to join our growing team of product, technology, and software professionals. The successful candidates will work with a highly experienced, senior engineering team, and have an opportunity9/24/2014 Annapolis, MD Save This Job


text:
Body Mind Wellness at COC: Life After Domestic Violence [1]
The College of the Canyons is presenting a series of workshops revolving around resiliency. "Life After Domestic Violence" is being presented by Linda Davies, Executive Director of the Domestic Violence Center of Santa Clarita Valley, at the COC Staff Dining Room. The workshop will help spread awareness about the importance of resiliency and empowerment after domestic violence; along with what resources are out there for survivors.
College of the Canyons- Staff Dining Room
26455 Rockwell Canyon Road
Santa Clarita California 91355United States